Matthew Onsum

906 total citations
24 papers, 633 citations indexed

About

Matthew Onsum is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthew Onsum has authored 24 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthew Onsum's work include HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). Matthew Onsum is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). Matthew Onsum collaborates with scholars based in United States, United Kingdom and Spain. Matthew Onsum's co-authors include Christopher V. Rao, Ulrik B. Nielsen, Emily Pace, Charlotte F. McDonagh, Birgit Schoeberl, Violette Paragas, Kwok‐Kin Wong, Jeffrey A. Engelman, Zandra E. Walton and Youngchul Song and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Matthew Onsum

22 papers receiving 618 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Onsum United States	10	313	301	217	89	81	24	633
Erika Kovács Hungary	9	324 1.0×	645 2.1×	256 1.2×	113 1.3×	104 1.3×	13	912
C. Moeder United States	8	225 0.7×	393 1.3×	114 0.5×	39 0.4×	68 0.8×	9	584
Lene Melsæther Grøvdal Denmark	11	361 1.2×	560 1.9×	186 0.9×	98 1.1×	236 2.9×	13	893
Rumana Rashid United States	16	215 0.7×	588 2.0×	126 0.6×	37 0.4×	43 0.5×	60	1.0k
Tae Hyun Hwang United States	17	300 1.0×	503 1.7×	109 0.5×	129 1.4×	66 0.8×	49	992
Peter A. Hoyne Australia	8	606 1.9×	677 2.2×	550 2.5×	126 1.4×	52 0.6×	10	1.1k
Nicolas Béry France	13	212 0.7×	762 2.5×	350 1.6×	25 0.3×	91 1.1×	28	932
Eliezer Shochat Switzerland	12	234 0.7×	302 1.0×	45 0.2×	55 0.6×	57 0.7×	17	588
Amanda Tracz United States	10	227 0.7×	283 0.9×	66 0.3×	116 1.3×	50 0.6×	14	679
Nobu Oshima Japan	11	166 0.5×	243 0.8×	91 0.4×	73 0.8×	56 0.7×	30	506

Countries citing papers authored by Matthew Onsum

Since Specialization

Citations

This map shows the geographic impact of Matthew Onsum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Onsum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Onsum more than expected).

Fields of papers citing papers by Matthew Onsum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Onsum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Onsum. The network helps show where Matthew Onsum may publish in the future.

Co-authorship network of co-authors of Matthew Onsum

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Onsum. A scholar is included among the top collaborators of Matthew Onsum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Onsum. Matthew Onsum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jagadeesh, Deepa, Steve Horwitz, Nancy L. Bartlett, et al.. (2022). Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. The Oncologist. 27(10). 864–873. 28 indexed citations

Pusztai, Lajos, Hailing Lu, Anne Große-Wilde, et al.. (2020). 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients. Regular and Young Investigator Award Abstracts. A198–A199. 3 indexed citations

Arkin, Adam P., et al.. (2020). Numerical computation of diffusion on a surface. UNC Libraries.

Radford, John, Joseph M. Connors, Anas Younes, et al.. (2019). EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematological Oncology. 37(S2). 290–291.

Jagadeesh, Deepa, Sarah McCue Horwitz, Nancy L. Bartlett, et al.. (2019). Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.. Journal of Clinical Oncology. 37(15_suppl). 7543–7543. 7 indexed citations

Jagadeesh, Deepa, Sarah McCue Horwitz, Nancy L. Bartlett, et al.. (2019). RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B‐CELL LYMPHOMAS. Hematological Oncology. 37(S2). 470–471. 4 indexed citations

Kirouac, Daniel C., Jinyan Du, Johanna Lahdenranta, et al.. (2016). HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Computational Biology. 12(4). e1004827–e1004827. 32 indexed citations

Kudla, Arthur J., Violette Paragas, Elena Geretti, Matthew Onsum, & Charlotte F. McDonagh. (2014). Potential regulators of HER2 activity in HER2-overexpressing gastric and gastroesophageal tumors: Analysis of HER3 and heregulin expression.. Journal of Clinical Oncology. 32(3_suppl). 48–48. 1 indexed citations

Onsum, Matthew, Elena Geretti, Violette Paragas, et al.. (2013). Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients. American Journal Of Pathology. 183(5). 1446–1460. 72 indexed citations

10.

Lahdenranta, Johanna, Violette Paragas, Arthur J. Kudla, et al.. (2013). Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer.. Journal of Clinical Oncology. 31(4_suppl). 48–48. 3 indexed citations

11.

Kirouac, Daniel C., Johanna Lahdenranta, Ryan Overland, et al.. (2013). Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors. Science Signaling. 6(288). ra68–ra68. 85 indexed citations

12.

Zhang, Bo, Johanna Lahdenranta, Jinyan Du, et al.. (2013). Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer.. Cancer Research. 73(8_Supplement). 4633–4633. 9 indexed citations

13.

Geretti, Elena, Violette Paragas, Matthew Onsum, et al.. (2012). Abstract P1-07-03: Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis. Cancer Research. 72(24_Supplement). P1–7. 2 indexed citations

14.

Zhang, Bo, Stephanie A. Nguyen, Alexandra Huhalov, et al.. (2012). Abstract 1888: MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth. Cancer Research. 72(8_Supplement). 1888–1888. 3 indexed citations

15.

Sequist, Lecia V., Manuel Modiano, Olivier Rixe, et al.. (2011). Abstract C27: Targeting ErbB3 and EGFR in lung cancer patients: A phase I trial of MM-121 in combination with erlotinib in patients with non-small cell lung cancer (NSCLC).. Molecular Cancer Therapeutics. 10(11_Supplement). C27–C27. 1 indexed citations

16.

Schoeberl, Birgit, Anthony C. Faber, Danan Li, et al.. (2010). An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation. Cancer Research. 70(6). 2485–2494. 215 indexed citations

17.

Onsum, Matthew & Christopher V. Rao. (2009). Calling heads from tails: the role of mathematical modeling in understanding cell polarization. Current Opinion in Cell Biology. 21(1). 74–81. 33 indexed citations

18.

Onsum, Matthew & Christopher V. Rao. (2007). A Mathematical Model for Neutrophil Gradient Sensing and Polarization. PLoS Computational Biology. 3(3). e36–e36. 67 indexed citations

19.

Onsum, Matthew, Kit Wong, Paul Herzmark, Henry R. Bourne, & Adam P. Arkin. (2006). Morphology matters in immune cell chemotaxis: membrane asymmetry affects amplification. Physical Biology. 3(3). 190–199. 19 indexed citations

20.

Schwartz, Peter, David Adalsteinsson, Phillip Colella, Adam P. Arkin, & Matthew Onsum. (2005). Numerical computation of diffusion on a surface. Proceedings of the National Academy of Sciences. 102(32). 11151–11156. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact